37 results about "CXCL13" patented technology

This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.

The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.

The invention provides preparation and application of CXCL13 cytokine chemotaxis type CAR-T cells, and particularly engineering immunocyte. The engineering immunocyte can express chimeric antigen receptors CAR and CXCR5 targetting MICA. The engineering immunocyte can selectively kill tumor cells, such as tumor cells high in expression of NKG2D ligands or NKG2D ligands and CXCL13 at the same time,and besides, the CAR-T cells disclosed by the invention have notable killing effects on the tumor cells.

The invention discloses CXCL13 oncoprotein and an application of targeted medicine for the CXCL13 oncoprotein in the tumor aspect. A method for preparing the tumor targeted medicine includes the steps of screening antibodies capable of effectively reducing the high expression of the CXCL13 oncoprotein or neutralizing the activity of the CXCL13 oncoprotein; preparing the corresponding tumor targeted medicine through the antibodies. According to the CXCL13 oncoprotein and the application, the anti-CXCL13 monoclonal antibodies can achieve the good anti-tumor effect by suppressing a p-AKT signal channel, a p-ERK signal channel and an EMT signal channel and accordingly suppressing growth, invasion and metastasis of tumor cells.

Methods for preventing or inhibiting inflammation in a subject are disclosed. In one aspect, the method comprises administering to a subject diagnosed with an inflammatory disease an effective amount of an anti-inflammatory agent that (1) inhibits the expression of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, or (2) inhibits the interaction between CXCR3 and CXCL9, CXCL10 or CXCL11, or between CXCR5 and CXCLl 3, or (3) inhibits a biological activity of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, wherein the agent comprises an antibody, antibody fragment, short interfering RNA (siRNA), aptamer, synbody, binding agent, peptide, aptamer-siRNA chimera, single stranded antisense oligonucleotide, triplex forming oligonucleotide, ribozyme, external guide sequence, or an agent-encoding expression vector.

The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.

Biomarkers predictive of a subject's likelihood of responding to an immunotherapy including blockade of PD-1 inhibitory signaling, and method of use thereof are disclosed. The biomarkers are HIF1-alpha, KDR, CXCL13, and IL7R. Exemplary methods include identifying or selecting a subject who may benefit from treatment with an immunotherapy including blockade of PD-1 signaling, and methods of predicting responsiveness of a subject suffering from cancer to treatment with an immunotherapy including blockade of PD-1 signaling. Preferred immunotherapies and methods of treating subjects with cancer are also provided.

The invention provides a CXCL13 (chemokine(C-X-C motif) ligand 13) DNA vaccine and an application thereof. According to the CXCL13 DNA vaccine, overall-length cDNA of CXCL13 and HBc (Hepatitis B core) are connected, and a vector is pcDNA 3.1(-). A tumor targeted drug prepared from the CXCL13 DNA vaccine generates stronger humoral immunity response by stimulating an active immunity system of an organism and can inhibit p-AKT, p-ERK and EMT signal pathways, thereby inhibiting tumor cell growth as well as invasion and metastasis and realizing the anti-tumor effect.

The invention provides application of a CXCL13 detection agent in preparation of a kit for predicting an immunotherapy effect. The CXCL13 detection agent is a reagent for detecting the expression level of CXCL13 in tumor specific T cells. The invention also provides a kit for predicting the immunotherapy effect. The kit comprises the CXCL13 detection agent. The invention also provides a method forpredicting the immunotherapy effect by detecting the expression level of CXCL13 in tumor specific T cells. The CXCL13 detection agent can be used for effectively and accurately detecting the expression level of CXCL13 and predicting the immunotherapy effect through the expression level.

Methods for treating diseases associated with CXCL13 expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity.

The invention provides a TCR-T cell for killing tumors, which is characterized in that the TCR-T cell is a T cell carrying a tumor antigen TCR, TCR in the TCR-T cells is derived from any one or more of the following T cells: 1) CD4T cells for expressing one or more of genes such as TNFRSF18, CXCL13, TNFRSF4, TNFSF8, ENTPD1, ACP5, LAYN, TNFRSF9, CTLA4, CD200 and TIGIT in tumors; and 2) a CD8T cellfor expressing one or more of the genes of TNFRSF18, CXCL13, CXCR6, GALNT2, ENTPD1, ACP5, HAVCR2, LAYN, TNFRSF9, CTLA4 and CD109 in the tumor. The TCR-T cell provided by the invention can be effectively applied to treatment of tumors, especially immunotherapy.

The invention provides methods and compositions for determining whether an individual is at risk of developing, or has, one or more angiogenic disorders. The methods detect the presence and/or amount of one or more genes or gene products in a sample, including a RORA, CRIM1, CXCR4, C5orf26, IGHG3, NALP2, PLA2G4A, IGLJ3, SHQ1, UCHL1, TANC1, PKP2, DNAJC6, C6orf105, NALP1, RGS13, CXCL13, RPS6KA2, MMP7, IL1A, ABCA1, VCAN, KIAA0888, ENPP2, and FAM38B gene or gene product. In addition, the invention provides methods for using one or more of these genes or gene products as a target for preventing or delaying the onset of one or more angiogenic disorders or treating a patient with one or more such disorders. The angiogenic disorder can be, for example, an ocular angiogenic disorder, for example, a disorder associated with choroidal neovascularization, for example, age-related macular degeneration.

The invention belongs to the field of medicines, and particularly relates to use of active substances such as an antibody protein, a nucleic acid sequence and a small molecule inhibitor for reducing the activity or expression quantity of CXCL13 protein in preparing medicines for treating malignant tumor metastasis. The technical problem to be solved is to provide a targeted therapeutic solution for immunoregulatory molecules of B cells. The targeted therapeutic solution is to provide the use of the active substances for reducing the activity or expression quantity of the CXCL13 protein in preparing the medicines for treating the malignant tumor metastasis. Experiments show that a CXCL13 blocking agent or blocking antibody can significantly inhibit the lung metastasis of malignant tumors; and by combination of the CXCL13 blocking agent or blocking antibody with chemotherapeutics or T cell immune negative regulators, the inhibition on the lung metastasis of the malignant tumors is particularly effective, and a better synergic effect can be obtained. A new and effective choice for the treatment of the malignant tumor metastasis is provided.

The invention provides use of CXCL13 as a biomarker in preparation or screening of diagnostic reagent for monilial infection. The use shows that CXCL13 can be taken as a novel biomarker for diagnosinginvasive monilial infection; and an in-vivo animal experiment shows that the expression level of CXCL13 can be increased by candidas of different strains, and the high expression of CXCL13 is in positive correlation with the seriousness of diseases, so that CXCL13 provided by the invention can be taken as a diagnostic and prognostic indicator for the invasive monilial infection.

Provided are methods of producing gene expression profiles of subjects having cancer. In certain aspects, the methods include contacting a sample obtained from breast tumor tissue (e.g., breast tumor tissue of a Luminal A molecular subtype) with reagents for determining the expression levels of ZIC2, RGS16, SLC2A1, DDR2, PTPLAD1, CMTM8, and TROAP. In some aspects, the methods include contacting a RNA sample obtained from breast tumor tissue (e.g., breast tumor tissue of a Basal molecular subtype) with reagents for determining the expression levels of CXCL13, CRYBB2, ITSN1, PLA1A, LAMC2, RGS5, WWC3, TTLL7, ANAPC1, TSSC1, CFH, HAUS4, RAMP3, MED28, TSC22D3, LSM14A, and ASIP. Kits that find use, e.g., in practicing the methods of the present disclosure, are also provided.

The present invention provides a device for predicting the therapeutic effect of immune checkpoint blockade therapy and its application. The device for predicting the therapeutic effect of immune checkpoint blockade therapy includes: a detection module: detecting CD3 and CXCL13 double positive cells and /or CD8 and CXCL13 double-positive cells, and count the proportion of CD3 and CXCL13 double-positive cells in CD3 T cells and/or the proportion of CD8 and CXCL13 double-positive cells in CD8 T cells; analysis module: according to the statistical results , to judge. The present invention selects the ratio of CD3 and CXCL13 double-positive cells in CD3 T cells and/or the ratio of CD8 and CXCL13 double-positive cells in CD8 T cells as a measure to predict the response of samples to immune checkpoint blockade therapy , the result is accurate and the applicability is strong.

The present disclosure is directed to methods and kits of use of serum biomarkers, including CXCL10, CXCL13, and/or sCD27, for predicting and evaluating therapeutic response to TNF inhibitor therapy in a patient in need thereof.